Eli Lilly and Company announced it has received marketing authorization for its Alzheimer's drug, donanemab, from India's Central Drugs Standard Control Organization (CDSCO). The approval allows for the treatment of adults with early symptomatic stages of Alzheimer's disease, including those with mild cognitive impairment or mild dementia who have confirmed amyloid plaque pathology. Donanemab is a disease-modifying therapy designed to help the body clear the amyloid plaques that build up in the brain and are linked to the cognitive decline seen in Alzheimer's. The intravenous treatment represents a significant step forward in making new therapeutic options available in a country with a growing health challenge related to dementia. This regulatory milestone opens a critical new market for one of Lilly's most important drugs. India's rapidly aging population means the number of people living with dementia is expected to grow significantly, highlighting the importance of early diagnosis and access to new treatments like donanemab.